A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer.

Summary: For women fighting metastatic breast cancer, finding the right treatment sequence is crucial. Many patients start with drugs called "non-steroidal aromatase inhibitors" (NSAIs) to stop the cancer from growing. But what happens if the cancer adapts and the drug stops working? A new review of medical studies offers hope. It suggests that switching to a slightly different type of drug—a "steroidal aromatase inhibitor" (SAI)—can still be effective. Even though both drugs target the same hormone process, they work differently enough that the second one can often "trick" the cancer again. This switch appears to be a reasonable and beneficial strategy, giving patients more valuable time and options.